Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial
Haas, Naomi B, Manola, Judith, Uzzo, Robert G, Flaherty, Keith T, Wood, Christopher G, Kane, Christopher, Jewett, Michael, Dutcher, Janice P, Atkins, Michael B, Pins, Michael, Wilding, George, Cella,Language:
english
Journal:
The Lancet
DOI:
10.1016/S0140-6736(16)00559-6
Date:
March, 2016
File:
PDF, 505 KB
english, 2016